Lv6
2458 积分 2020-07-27 加入
Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells
5天前
已完结
Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1
29天前
已关闭
An MDM2 degrader for treatment of acute leukemias
1个月前
已完结
Tgrx-678, a Novel Allosteric Inhibitor of BCR-ABL1, Demonstrates Preclinical Anti-Leukemia Activity, High Oral Bioavailability and Synergism with Ponatinib to Suppress the Highly Resistant Compound Mutations
2个月前
已关闭
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
2个月前
已完结
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis
2个月前
已完结
Targeting MDM2 in Soft-Tissue Sarcomas (and Other Solid Tumors): The Revival?
2个月前
已完结
Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
3个月前
已完结
The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug
3个月前
已完结
A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia
3个月前
已完结
皖公网安备34019202002308
